Receptor tyrosine kinases-instructed release of its inhibitor from hydrogel to delay ovarian aging

Zhonghua Shi,Xiaoyan Li,Mengxing Wei,Peiyao Chen,Ting Zhang,Xiufeng Ling,Junqiang Zhang,Chun Zhao,Fuqiang Wang,Gaolin Liang
DOI: https://doi.org/10.1016/j.biomaterials.2020.120536
IF: 14
2021-02-01
Biomaterials
Abstract:<p>Premature ovarian failure (POF) is the most frequently occured disease in ovary. Direct inhibition of mammalian target of rapamycin (mTOR) activity can treat woman POF but brings adverse effects to women. Herein, by rational design of a hydrogelator Nap-Phe-Phe-Asp-Arg-Leu-Tyr-OH (<strong>Y</strong>) and co-assembling <strong>Y</strong> with an inhibitor of receptor tyrosine kinase (RTK, an upstream kinase of mTOR), Ala-Glu-Ala-Ala-Leu-Tyr-Lys-Asn-Leu-Leu-His-Ser-OH (<strong>Inh</strong>), to form hydrogel Gel <strong>Y+Inh</strong>, we develop a "smart" strategy of RTK-responsive disassembly of the hydrogel to release <strong>Inh</strong>. Release of <strong>Inh</strong> moderately inhibits the activity of mTOR and therefore delays ovarian aging. Oocyte and zygote experiments show that Gel <strong>Y+Inh</strong> improves both meiotic maturation of the oocytes and early embryonic development of the zygotes. <em>In vivo</em> animal experiments indicate that Gel <strong>Y+Inh</strong> effectively delays ovarian aging in aged mice by down regulation of mTOR activity, stimulation of ovaries to secrete estrogen and progesterone, and development of more antral follicles for reproduction. We expect that our new hydrogel Gel <strong>Y+Inh</strong> could be applied to treat woman POF, as well as delay ovarian aging, in clinic in the near future.</p>
engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?